Contraindicated in:
Use Cautiously in:
Chlorpheniramine
CV: hypertension, arrhythmias, hypotension, palpitations.
EENT: blurred vision.
GI: dry mouth, GI obstruction, constipation.
GU: urinary hesitancy, urinary retention.
Neuro: confusion, drowsiness, sedation, dizziness, dysphoria, euphoria, excitation (in children), floating feeling, hallucinations, headache, unusual dreams.
Codeine
CV: hypotension, bradycardia.
Derm: flushing, sweating.
EENT: blurred vision, diplopia, miosis.
GI: constipation, nausea, vomiting.
GU: urinary retention.
Resp: RESPIRATORY DEPRESSION.
Misc: physical dependence, psychological dependence, tolerance.
Drug-Drug:
Therapeutic Classification: allergy, cold and cough remedies, antitussives
Pharmacologic Classification: antihistamines, opioid agonists
Chlorpheniramine
Absorption: Well absorbed following oral administration; polistirex delays absorption, prolonging action.
Distribution: Widely distributed. Crosses the blood-brain barrier.
Metabolism/Excretion: Extensively metabolized by the liver.
Half-life: 1215 hr.
Codeine
Absorption: 50% absorbed from the GI tract; polistirex delays absorption, prolonging action.
Distribution: Widely distributed.
Protein Binding: 7%.
Metabolism/Excretion: Mostly metabolized by the liver (primarily via the CYP2D6 isoenzyme); 10% converted to morphine;the CYP2D6 enzyme system exhibits genetic polymorphism (some patients [110% Whites, 3% African Americans, 1628% North Africans/Ethiopians/Arabs] may be ultra-rapid metabolizers and may have ↑ morphine concentrations and an ↑ risk of adverse effects); 515% excreted unchanged in urine.
Half-life: 2.54 hr.